BioSpace News Archive

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will report its financial results for the full year December 31, 2022 after market close on Friday, March 31, 2023.

FemDx Medsystems, Inc., a women’s health startup based in Santa Clara, CA announces the company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its FalloView™ device.

Translational Research In Oncology (TRIO) today announced positive topline results from NATALEE (TRIO033), a Novartis sponsored Phase III trial of ribociclib plus endocrine therapy (ET) as adjuvant treatment for patients with stages II and III early breast cancer (EBC) at risk of disease recurrence.

BioDuro-Sundia announced today the establishment of a Discovery Research Scientific Advisory Board (SAB) with the appointment of Andrew Thomas Ph.D. and Zach Sweeney Ph.D. as its members.

Merck KGaA, Darmstadt, Germany regains exclusive worldwide rights to develop, manufacture and commercialize BAVENCIO from Pfizer.

Midatech Pharma PLC is pleased to announce a new research programme coded MTD217 focusing on developing new therapeutic options for metastatic cancers with high unmet needs.

Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), announced the presentation of three posters featuring preclinical data at the upcoming 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, from April 14 to 19, 2023.

NLS Pharmaceutics Ltd. today announced the final results from its Open Label Extension (OLE) Study for Quilience® (Mazindol ER) in the treatment of narcolepsy.

Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), the parent company of BioKey and affiliate of BioStrand, announced today that the EPO has issued a “Decision to Grant” for BioKey’s patent application covering the company’s HYFT® Technology used to organize and analyze biological sequence information.

Barrow Neurological Institute at Phoenix Children’s, one of the largest pediatric neuroscience programs in the country, announced the appointment of Neil Friedman, MBChB as director.